(06 Feb 2020)
Dublin, Ireland, February 6th, 2020 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced the appointment of Murray Yule, M.D., Ph.D., as its Chief Medical Officer. Dr. Yule brings to Inflection Biosciences extensive experience leading clinical development programs in oncology, and he will lead the clinical development and medical affairs of the company as it advances its oncology pipeline including IBL-202, a first-in-class dual PIM kinase and PI3K inhibitor.
Dr. Yule commented “I am excited to be joining Inflection Biosciences at this time as we move towards the clinical introduction of IBL-202 for the treatment of patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkins Lymphoma. IBL-202, a first-in-class dual PIM and PI3K inhibitor, has been shown to be ten times more active than existing PI3K inhibitors in models of CLL.”
Darren Cunningham, CEO of Inflection Biosciences, added “We are very pleased to welcome Murray to Inflection Biosciences. Murray, a highly experienced physician, brings considerable track record in the successful translation and clinical development of new targeted cancer therapeutics. His addition to the team further underpins the company’s commitment to advancing important new therapeutics to address significant unmet needs in cancer.”
Murray Yule is a board certified medical oncologist who trained in the United Kingdom and also at the MD Anderson Cancer Centre in Houston, Texas. He gained his PhD in anticancer therapeutics at the University of Newcastle and he is a member of the Royal College of Physicians of the UK. He has more than seventeen years’ experience in the Pharma Industry and has a broad experience of the development of early anticancer therapeutics having successfully filed multiple INDs and CTA applications exploring previously unrecognized cancer targets. In addition, Dr. Yule has published more than twenty papers in his career in the cancer space.
Whilst working at Eisai, Dr. Yule led the team that successfully achieved global market approval of eribulin for the treatment of metastatic breast cancer. As the Medical Director of Astex Therapeutics, he was instrumental in its merger with Supergen Inc. and ultimately its acquisition by Otsuka Pharmaceutical. As a former part of the BerGenBio ASA management team he contributed to its successful IPO on the Norwegian exchange in 2017. As a biotechnology medical officer Dr. Yule has successfully formed and driven translational and clinical collaborations with larger pharma including Novartis (small molecules leading to the development of ribociclib) and Merck (Immuno-oncology).
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the first-in-class AUM300 series (PIM/PI3K/mTOR inhibitors) partnered with AUM Biosciences, internal programs IBL-202 (PIM/PI3K inhibitor) and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com